摘要
目的:观察拉米夫定对慢性乙型肝炎患者肝脏基质金属蛋白酶-1(MMP-1)及金属蛋白酶组织抑制因子-1(TIMP-1)的影响,探讨其防治肝纤维化的作用。方法:25例慢性乙型肝炎患者予拉米夫定100mg/d,连用1年,治疗前后作2次肝穿活捡,常规HE染色及Gordon Sweet、Masson染色,作炎性活动度及纤维化程度计分,作MMR-1、TIMP-1的免疫组化学分析。结果:25例患者中21例HBV DNA转阴,炎性活动度计分由5.40±3.04降至3.88±1.42(P<0.01),纤维化程度计分由3.44±1.45降至3.16±1.34(P<0.05),MMP-1由3.142±0.024增至4.009±0.310(P<0.05),TIMP-1由5.063±0.610降为4.107±0.131(P<0.05)。结论:拉米夫定强效抑制HBV,使肝脏TIMP-1活性降低、MMP-1活性增强而起到防治肝纤维化的作用。
Objective: Through observing the effects of Lamivudine on the MMP-1 and TIMP-1 in the livers of chronic hepatitis B patients, to discuss its fuction of preventing and curing liver fibrosis. Methods: 25 patients with chronic hepatitis B received 100 mg Lamivudine orally daily for 52 weeks. The livers biopsies were obtained before and after treatment. The sections were stained with HE, Gordon Sweet and Masson , and their grading of inflammation, of fibrosis were scored , and MMP-1 and TIMP-1 were examined by immunohistochemistry method. Result: Among the 25 patients 21 of them became HBV DNA negative during treatment . The score of the inflammation reduced from 5.40±3.04 to 3.88±1.42(P<0.01), while the fibrosis score reduced from 3.44 ± 1.45 to 3.16 ± 1.34 (P<0.05). MMP-1 were increased from 3.142 ±0.024 to 4.009±0.301 (P<0.05), and TIMP-1 were reduced from 5.063 + 0.610 to 4.107 + 0.131 (P<0.05). Conclusion: It is found that Lamivudine could inhibiti HBV, thus the activation of TIMP-1 was reduced and the activation of MMP-1 was enhanced, so it could take effect on preventing and curing liver fibrosis.
出处
《中西医结合肝病杂志》
CAS
2002年第4期205-206,共2页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
